Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer remains on track with interim data anticipated in mid-2024
Closed a $200 million oversubscribed private.
BYXE Week, which runs until Feb. 25, is meant to encourage people to ride despite winter and features scavenger hunts, free drinks, prizes for selfies and more.
StockWatch: Biogen s Q4 Results Disappoint Analysts genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
BOSTON and MONTREAL, Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. , a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive.
By Dean Seal The chief executive of EnGene Holdings intends to step down due to personal family and health reasons. The clinical-stage genetic-medicines.